Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

Lingzhi Yan, Xiaolan Shi, Jing Wang, Song Jin, Ying Yao, Panfeng Wang, Jingjing Shang, Yingying Zhai, Shuang Yan, Yun Xu, Jiajia Meng, Weiqin Yao, Xiao Ma, Chengcheng Fu, Depei Wu

Blood (2024) 144 (Supplement 1): 4750.

https://doi.org/10.1182/blood-2024-205595

Published: 2024

Journal Articles

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

Hongying You, Hongjie Shen, Song Jin, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 4325–4327.

https://doi.org/10.1182/blood-2022-159272

Published: 2022

Journal Articles

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Hongying You, Song Jin, Chunxiao Wu, Qingqing Wang, Shuang Yan, Yingying Zhai, Weiqin Yao, Xiaolan Shi, Jingjing Shang, Lingzhi Yan, Ying Yao, Jing Wang, Panfeng Wang, Jinlan Pan, Depei Wu, Chengcheng Fu

Blood (2022) 140 (Supplement 1): 10056–10057.

https://doi.org/10.1182/blood-2022-159067

Published: 2022

Journal Articles

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Yan Xie, MD, Chengcheng FU, MD PhD, Lingzhi Yan, MD PhD, Song Jin, MD, Jingjing Shang, MD, Xiaolan Shi, MD PhD, Jinlan Pan, MD, Yan Yin, MS, Tingting Mao, MS, Jing Deng, PhD, Douglas D. Fang, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD, Shuang Yan, MD, Yingying Zhai, MD, Ying Yao, MD, Panfeng Wang, MD, Jing Wang, MD, Depei Wu, MDPhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-139195

Published: 2020

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Xiaolan Shi, Lingzhi Yan, Jingjing Shang, Su Qu, Liqing Kang, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Shuang Yan, Yong Liu, Guanghua Chen, Ziling Zhu, Huirong Chang, Depei Wu, MDPhD, Lei Yu, ChengCheng Fu

Blood (2018) 132 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2018-99-117964

Published: 2018

Journal Articles

The Prognostic Significance of Minimal Residual Disease Detection after Induction and ASCT to the Patients with Multiple Myeloma

Weiqin Yao, Zhu Mingqing, Yao Feirong, Lingzhi Yan, Song Jin, Jingjing Shang, Ying Yao, Shuang Yan, Depei Wu, MD PhD, ChengCheng Fu

Blood (2018) 132 (Supplement 1): 4956.

https://doi.org/10.1182/blood-2018-99-118257

Published: 2018

Journal Articles

Application of the Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Yun Xu, Ying Yao, Weiqin Yao, Song Jin, Lingzhi Yan, Jingjing Shang, Chengcheng Fu, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5517.

https://doi.org/10.1182/blood.V130.Suppl_1.5517.5517

Published: 2017

Journal Articles

Comparative Outcomes of Immunochemotherapy with RCD (rituximab, cyclophosphamide, dexamethasone) and BCD (bortezomib, cyclophosphamide, dexamethasone) in Waldenstrom Macroglobulinaemia: NCT02971982

Jingjing Shang, Lingzhi Yan, Jin Zhou, Song Jin, Chengcheng Fu, Depei Wu, MD, Ying Yao

Blood (2017) 130 (Supplement 1): 5166.

https://doi.org/10.1182/blood.V130.Suppl_1.5166.5166

Published: 2017

Journal Articles

Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Lingzhi Yan, Jingjing Shang, Liqing Kang, Xiaolan Shi, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Guanghua Chen, Ziling Zhu, Huirong Chang, Depei Wu, MD, Lei Yu, Chengcheng Fu

Blood (2017) 130 (Supplement 1): 506.

https://doi.org/10.1182/blood.V130.Suppl_1.506.506

Published: 2017

Journal Articles

Evaluating Prognostic Value of Patients with Newly Diagnosed Multiple Myeloma By Serum Free Light Chain κ/λ Ratio in Combination with LDH

Chengcheng Fu, Panfeng Wang, Feiran Gong, Jiazi Zhou, Ying Yao, Yun Xu, Yang Xu, Huirong Chang, Depei Wu, MD PhD

Blood (2016) 128 (22): 5623.

https://doi.org/10.1182/blood.V128.22.5623.5623

Published: 2016

Journal Articles

Retrospective Analysis of 111 Cases of Multiple Myeloma Treated with Autologous Hematopoietic Stem Cell Transplantation

Chengcheng Fu, Yun Xu, Juan Wang, Jin Zhou, Ling Ma, Shuang Yan, Panfeng Wang, Ying Yao, Song Jin, Lingzhi Yan, Depei Wu, MDPhD

Blood (2016) 128 (22): 5833.

https://doi.org/10.1182/blood.V128.22.5833.5833

Published: 2016

Journal Articles

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 4718.

https://doi.org/10.1182/blood.V114.22.4718.4718

Published: 2009

Journal Articles

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Bing Chen, Wei-Li Zhao, Jie Jin, Yong-Quan Xue, Xin Cheng, Xiao-Ting Chen, Jing Cui, Zhi-Mei Chen, Qi Cao, Guang Yang, Ying Yao, Jian-Hua Tong, Jun-Min Li, Jue Chen, Shu-Min Xiong, Zhi-Xiang Shen, Zhu Chen, Sai-Juan Chen

Blood (2004) 104 (11): 1451.

https://doi.org/10.1182/blood.V104.11.1451.1451

Published: 2004

NARROW

Low Intensity Daratumumab to Treat Rersistent/Recurrent Minimal Residual Disease in Multiple Myeloma

TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing

The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Targeting 1q21 Amplification with APG2575 and Lenalidomide to Sensitize BCL-2 Inhibition with the Decrease of MCL-1 Protein in High Risk MM Models

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

The Prognostic Significance of Minimal Residual Disease Detection after Induction and ASCT to the Patients with Multiple Myeloma

Application of the Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Comparative Outcomes of Immunochemotherapy with RCD (rituximab, cyclophosphamide, dexamethasone) and BCD (bortezomib, cyclophosphamide, dexamethasone) in Waldenstrom Macroglobulinaemia: NCT02971982

Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Evaluating Prognostic Value of Patients with Newly Diagnosed Multiple Myeloma By Serum Free Light Chain κ/λ Ratio in Combination with LDH

Retrospective Analysis of 111 Cases of Multiple Myeloma Treated with Autologous Hematopoietic Stem Cell Transplantation

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only